CAR-T

J&J inks Fate deal to move into allogeneic CAR therapies
J&J inks Fate deal to move into allogeneic CAR therapies
Fierce Biotech
JNJ
Fate Therapeutics
CAR NK
CAR-T
cell therapies
drug development
Flag link:
Motion denied: Gilead still on the hook for $1.5B in damages over CAR-T patent dispute with Bristol Myers Squibb
Motion denied: Gilead still on the hook for $1.5B in damages over CAR-T patent dispute with Bristol Myers Squibb
Endpoints
Gilead Sciences
CAR-T
Bristol-Meyers Squibb
Juno Therapeutics
patents
Flag link:
Daiichi Sankyo submits application for CAR T therapy axicabtagene ciloleucel to treat patients with certain relapsed/refractory B-cell lymphomas in Japan
Daiichi Sankyo submits application for CAR T therapy axicabtagene ciloleucel to treat patients with certain relapsed/refractory B-cell lymphomas in Japan
Pharmaceutical Business Review
Daiichi Sankyo
Japan
CAR-T
axicabtagene ciloleucel
relapsed or refractory diffuse large B-cell lymphoma
Flag link:
Just in time to assure a decision before CVR deadline, Bristol Myers Squibb files NDA for Celgene/bluebird CAR-T
Just in time to assure a decision before CVR deadline, Bristol Myers Squibb files NDA for Celgene/bluebird CAR-T
Endpoints
Bristol-Meyers Squibb
CAR-T
Celgene
ide-cel
Bluebird Bio
liso-cel
ozanimod
Flag link:
AbbVie-backed Carisma's 'CAR-M' tech shrinks tumors in mouse models of ovarian cancer
AbbVie-backed Carisma's 'CAR-M' tech shrinks tumors in mouse models of ovarian cancer
Fierce Biotech
ovarian cancer
Carisma Therapeutics
CAR-M
CAR-T
Flag link:
J&J's favorite CAR-T developer, currently owned by a Chinese CRO, is laying the groundwork for US IPO
J&J's favorite CAR-T developer, currently owned by a Chinese CRO, is laying the groundwork for US IPO
Endpoints
CAR-T
IPOs
GenScript
CROs
China
JNJ
Flag link:
Scorpion Venom Could Improve Immuno-Oncology Therapies in Brain Cancer
Scorpion Venom Could Improve Immuno-Oncology Therapies in Brain Cancer
BioSpace
brain cancer
drug development
CAR-T
City of Hope
scorpion venom
Flag link:
Morphosys’ off-the-shelf rival to CAR-T approaches finish line with a speedy review
Morphosys’ off-the-shelf rival to CAR-T approaches finish line with a speedy review
Endpoints
MorphoSys
Gilead Sciences
Novartis
CAR-T
tafasitamab
DLBCL
Flag link:
Cellectis boosts its coffers in revised off-the-shelf CAR-T deal with Servier
Cellectis boosts its coffers in revised off-the-shelf CAR-T deal with Servier
Endpoints
CAR-T
Cellectis
Servier
UCART19
Flag link:
Bristol-Myers' CAR-T gets priority review, mid-August PDUFA date
Bristol-Myers' CAR-T gets priority review, mid-August PDUFA date
Fierce Biotech
Bristol-Myers Squibb
FDA
lisocabtagene maraleucel
priority review
CAR-T
Flag link:
Gilead closes in on second CAR-T approval in US
Gilead closes in on second CAR-T approval in US
Pharmaforum
FDA
Gilead Sciences
Kite Pharma
mantle cell lymphoma
CAR-T
Flag link:
CAR-T tackles multiple myeloma by using the target CD229 to kill cancer stem cells
CAR-T tackles multiple myeloma by using the target CD229 to kill cancer stem cells
Fierce Biotech
CAR-T
Multiple Myeloma
CD229
JNJ
Bluebird Bio
Flag link:
Scripps Research’s Calibr to Test “Switchable” CAR-T in Clinical Trial
Scripps Research’s Calibr to Test “Switchable” CAR-T in Clinical Trial
Xconomy
Scripps Research Institute
Calibr
CAR-T
Flag link:
MD Anderson emerges with strong evidence for natural killer cell therapy, and Takeda looks like a winner
MD Anderson emerges with strong evidence for natural killer cell therapy, and Takeda looks like a winner
Endpoints
Takeda
MD Anderson
natural killer cell therapy
CAR-T
Flag link:
Adaptimmune and Astellas to Co-Develop Allogenic CAR-T and TCR T-Cell Therapies
Adaptimmune and Astellas to Co-Develop Allogenic CAR-T and TCR T-Cell Therapies
BioSpace
Adaptimmune
SPEAR-T
Astellas
CAR-T
cell therapy
drug development
Flag link:
Merck-partnered biotech hands Roche its half-life extension tech as it pivots to immuno-oncology
Merck-partnered biotech hands Roche its half-life extension tech as it pivots to immuno-oncology
Endpoints
Roche
immuno-oncology
Amunix
Merck
CAR-T
Flag link:
Docs are excited about CAR-T, BTK drugs, survey finds. How can pharma best promote them?
Docs are excited about CAR-T, BTK drugs, survey finds. How can pharma best promote them?
Fierce Pharma
physicians
oncologists
Multiple Myeloma
CAR-T
Flag link:
Bristol-Myers unloads old-school plant as it readies for CAR-T future
Bristol-Myers unloads old-school plant as it readies for CAR-T future
Fierce Pharma
Bristol-Myers Squibb
Celgene
CAR-T
M&A
Flag link:
3 trends in biotech to watch in 2020
3 trends in biotech to watch in 2020
Stat
IPOs
eteplirsen
CAR-T
gene therapy
cell therapy
biotech
Flag link:
Pharma's gene and cell therapy ambitions will kick into high gear in 2020—despite some major hurdles
Pharma's gene and cell therapy ambitions will kick into high gear in 2020—despite some major hurdles
Fierce Pharma
gene therapy
reimbursement
drug manufacturing
Bristol-Myers Squibb
Pfizer
Biomarin
Sarepta Therapeutics
Gilead Sciences
CAR-T
Flag link:

Pages